SMAD4 Y353C promotes the progression of PDAC

• Published in: BMC cancer Vol. 19; no. 1; pp. 1037 - 12
• Main Authors: Wang, Zusen, Li, Yongxing, Zhan, Shixiong, Zhang, Lu, Zhang, Shun, Tang, Qian, Li, Miaomiao, Tan, Zhen, Liu, Shiguo, Xing, Xiaoming
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.11.2019; BioMed Central; BMC
• Subjects: Adenocarcinoma; Analysis; Cadherins - metabolism; Cancer; Cancer metastasis; Carcinogenesis; Carcinoma; Carcinoma, Pancreatic Ductal - genetics; Cell Line, Tumor; Cell Movement; Cell Proliferation; Development and progression; DNA sequencing; E-cadherin; Female; Gene Expression Regulation, Neoplastic; Genes; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Mutation, Missense - genetics; Novels; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pancreatic Neoplasms - genetics; Prognosis; Scientific equipment industry; SMAD4; Smad4 Protein - genetics; Smad4 Protein - metabolism; Tumors; Vimentin; Vimentin - metabolism; United States; China; Vimentin; SMAD4; Mutation; E-cadherin; Pancreatic ductal adenocarcinoma

SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Abnormal SMAD4 expression also plays an important role in the malignant progression of PDAC. We investigated SMAD4 status in PDAC by immunohistochemical methods to explore the relationshi...